Radiofrequency ablation for renal cell carcinoma using a switchin controller

Radiofrequency ablation for renal cell carcinoma using a switchin controller - RFA for renal cell carcinoma using a switchin controller

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002506

Enrollment

Registered

2009-09-16

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal cell carcinoma

Interventions

12-month enrollment. 12-month follow-up. Number of subjects: 33.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with renal cell carcinoma diagnosed by biopsy. 2. The maximum diameter of10cm or smaller. 3. Not a surgical candidate. 4. No abnormal function in the main organs. a) white blood count of 3000/mm3. b) Hgb of 8.0g/dl or more. c) Cr of 2.0 mg/dl or less. d) SpO2 of 92% or more. e) bil of 2.0mg/dl or less. 5. Age of 20 years or more. 6. PS of 0 or 1. 7. Life-expectancy of 2 months or longer. 8. Informed consent from the patient.

Exclusion criteria

Exclusion criteria: 1. Abnormal coagulability a) platelet count of 50000/mm3 or less. b) INR greater than 1.5.

Design outcomes

Primary

Measure	Time frame
Evaluation of adverse effects after radiofrequency ablation.	—

Countries

Japan

Contacts

Public Contactkoichiro Yamakado

Mie University Hospital Department of Radiology

yama@clin.medic.mie-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026